$2.63 Billion is the total value of SECTORAL ASSET MANAGEMENT INC's 77 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MYL | New | MYLAN N V | $71,626,000 | – | 1,206,838 | +100.0% | 2.72% | – |
| MDT | New | MEDTRONIC PLCshares | $31,830,000 | – | 408,126 | +100.0% | 1.21% | – |
| TTPH | New | TETRAPHASE PHARMAC | $22,182,000 | – | 605,393 | +100.0% | 0.84% | – |
| NVTA | New | INVITAE CORP | $14,655,000 | – | 874,391 | +100.0% | 0.56% | – |
| ASND | New | ASCENDIS PHARMA A Ssp adr | $12,694,000 | – | 731,660 | +100.0% | 0.48% | – |
| CI | New | CIGNA CORP | $9,898,000 | – | 76,465 | +100.0% | 0.38% | – |
| TGTX | New | TG THERAPEUTICS | $6,751,000 | – | 436,084 | +100.0% | 0.26% | – |
| IPXL | New | IMPAX LABS INC | $1,861,000 | – | 39,697 | +100.0% | 0.07% | – |
| LCI | New | LANNET INC | $1,736,000 | – | 25,634 | +100.0% | 0.07% | – |
| ENDP | New | ENDO INTL PLCshares | $1,676,000 | – | 18,688 | +100.0% | 0.06% | – |
| JAZZ | New | JAZZ PHARMA PLC | $1,625,000 | – | 9,405 | +100.0% | 0.06% | – |
| MCK | New | MCKESSON CORP | $1,582,000 | – | 6,995 | +100.0% | 0.06% | – |
| EARS | New | AURIS MED HLDG AG | $1,497,000 | – | 279,850 | +100.0% | 0.06% | – |
| ALKS | New | ALKERMES PLCshares | $1,388,000 | – | 22,770 | +100.0% | 0.05% | – |
| HZNP | New | HORIZON PHARMAshares | $1,337,000 | – | 51,476 | +100.0% | 0.05% | – |
| PCRX | New | PACIRA PHARMACEUTICALS | $1,238,000 | – | 13,939 | +100.0% | 0.05% | – |
| DEPO | New | DEPOMED INC | $1,224,000 | – | 54,632 | +100.0% | 0.05% | – |
| EGRX | New | EAGLE PHARMACEUTICALS | $927,000 | – | 22,123 | +100.0% | 0.04% | – |
| NKTR | New | NEKTAR THERAPEUTICS | $870,000 | – | 79,115 | +100.0% | 0.03% | – |
| CBM | New | CAMBREX CORP | $463,000 | – | 11,673 | +100.0% | 0.02% | – |
| CTLT | New | CATALENT INC | $445,000 | – | 14,293 | +100.0% | 0.02% | – |
| CHRS | New | COHERUS BIOSCIENCES | $387,000 | – | 12,656 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOMARIN PHARMAC INC | 45 | Q2 2024 | 6.7% |
| DR REDDYS LABS LTD | 45 | Q2 2024 | 2.0% |
| PTC THERAPEUTICS INC | 43 | Q2 2024 | 2.7% |
| GILEAD SCIENCES INC | 41 | Q2 2024 | 8.4% |
| VERTEX PHARMACEUTICL | 41 | Q2 2024 | 6.0% |
| INCYTE CORPORATION | 41 | Q2 2024 | 5.2% |
| AMICUS THERAPEUTICS INC | 40 | Q2 2024 | 6.6% |
| PFIZER INC | 38 | Q2 2024 | 6.3% |
| MERCK & CO. INC | 37 | Q2 2024 | 6.4% |
| MEDTRONIC PLC | 36 | Q2 2024 | 4.4% |
View SECTORAL ASSET MANAGEMENT INC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| eFFECTOR Therapeutics, Inc. | February 14, 2024 | 2,382,644 | 3.7% |
| Galera Therapeutics, Inc.Sold out | February 14, 2024 | 0 | 0.0% |
| Aprea Therapeutics, Inc. | February 12, 2021 | 163,681 | 0.8% |
| LA JOLLA PHARMACEUTICAL CO | February 13, 2020 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 13, 2018 | 1,426,862 | 4.4% |
| Advaxis, Inc. | February 10, 2017 | 690,074 | 1.7% |
| AMICUS THERAPEUTICS INC | February 10, 2017 | 5,100,198 | 3.6% |
| OncoMed Pharmaceuticals Inc | February 12, 2016 | ? | ? |
| IRONWOOD PHARMACEUTICALS INC | February 13, 2015 | ? | ? |
| SEQUENOM INC | February 12, 2014 | ? | ? |
View SECTORAL ASSET MANAGEMENT INC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-08-13 |
| N-PX | 2024-08-09 |
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-02-13 |
View SECTORAL ASSET MANAGEMENT INC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.